Brenntag has entered into an exclusive global distribution agreement with biotech startup Insempra for the latter’s innovative Omega-7 biolipid in beauty and personal care markets.
CosVivet ActiLipid O7 is said to be a next-generation biolipid that unites active performance, multifunctionality and sustainability in one powerful ingredient while additionally delivering premium sensory experience.
It is based on Insempra's Omega-7 biolipid, which is designed to meet demand for high-performance, sustainable beauty solutions.
CosVivetActiLipid O7 has been developed to support moisturization and help maintain smooth, supple-looking skin, making it particularly suitable for sensitive and delicate skin care applications.
CosVivet ActiLipid O7 combines multifunctional performance with a refined sensory profile, contributing to a silky, lightweight and non-greasy skin feel, effortless spreadability and an elegant finish.
It is fully oil-soluble, compatible with lipophilic raw materials and offers formulation flexibility across a wide range of skin care concepts. Produced through an advanced fermentation process, CosVivet ActiLipid O7 aligns with evolving sustainability expectations and supports responsible beauty innovation.
CosVivet ActiLipid O7 is a clear yellow liquid with minimal odour, high thermal stability and minimal impact on odour and colours in finished formulations.
It is fully soluble in oils, compatible with liposoluble raw materials and an alternative to oils like sea buckthorn and macadamia without heir variability issues.
Produced through precision fermentation, it features a strong environmental profile, aligned with modern sustainability expectations and therefore enables the creation of products that combine effective performance with environmental responsibility.
Michael Wilkop, Brenntag Specialties Regional President Beauty & Care EMEA, said: “We are excited to embark on this new offer which underscores our commitment to helping our customers access cutting-edge sustainable ingredients that meet evolving consumer demands.
“Insempra's expertise in industrial biotechnology combined with Brenntag's global distribution network, technical capabilities, and Innovation and Application Centres creates a powerful platform for delivering sustainable beauty solutions. This is the first of several innovative products we plan to introduce together,” he added.
Jens Klein, CEO and founder of Insempra, said: "This distribution agreement with Brenntag represents a pivotal moment for Insempra as we scale our biotechnology innovations to reach the global beauty industry.”
